5MJC BCU 6: Tumor Biomarker Changes After Presurgical Treatment of Patients with Breast Cancer with High-Dose Fulvestrant and Anastrozole
Tumor Biomarker Changes After Presurgical Treatment of Patients with Breast Cancer with High-Dose Fulvestrant and Anastrozole
5MJC BCU 3: Phase II Study of Trastuzumab-DM1 (T-DM1) for Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Phase II Study of Trastuzumab-DM1 (T-DM1) for Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
5MJC BCU 2: NCCTG-N9831: Adjuvant Chemotherapy Alone or with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in HER2-Positive Breast Cancer
NCCTG-N9831: Adjuvant Chemotherapy Alone or with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in HER2-Positive Breast Cancer
5MJC BCU 1: Efficacy of Trastuzumab-Based Regimens in Patients with HER2-Amplified Early-Stage Breast Cancer
Efficacy of Trastuzumab-Based Regimens in Patients with HER2-Amplified Early-Stage Breast Cancer
Year in Review - Lung Cancer Edition 2009
Year in Review - Lung Cancer Edition 2009 |
|---|
|
A CME monograph and speaker’s slide kit summarizing the year’s most important meeting presentations and journal articles.
|
5MJC MDS/AML 17: Links
Studies on the Efficacy and Safety of Deferasirox for Iron Chelation in Patients with MDS: EPIC and US03
5MJC MDS/AML 15: Safety and Efficacy of Combination Therapies with Azacitidine in Elderly Patients with AML or MDS
Safety and Efficacy of Combination Therapies with Azacitidine in Elderly Patients with AML or MDS
5MJC MDS/AML 16: Phase II Study of Maintenance Treatment with 5-Azacitidine for Patients with MDS or Post-MDS AML
Phase II Study of Maintenance Treatment with 5-Azacitidine for Patients with MDS or Post-MDS AML
5MJC MDS/AML 19: Patterns of Care Survey for Myelodysplastic Syndromes (MDS)
Patterns of Care Survey for Myelodysplastic Syndromes (MDS)
5MJC MDS/AML 17: Studies on the Efficacy and Safety of Deferasirox for Iron Chelation in Patients with MDS: EPIC and US03
Studies on the Efficacy and Safety of Deferasirox for Iron Chelation in Patients with MDS: EPIC and US03
5MJC MDS/AML 18: Lenalidomide Activity in AML with Trisomy 13
Lenalidomide Activity in AML with Trisomy 13
5MJC MDS/AML 14: Patterns of Care Survey for Acute Myeloid Leukemia (AML)
Patterns of Care Survey for Acute Myeloid Leukemia (AML)
5MJC MDS/AML 11: Five-Day Decitabine Therapy for Elderly Patients with Acute Myeloid Leukemia (AML)
Five-Day Decitabine Therapy for Elderly Patients with Acute Myeloid Leukemia (AML)
5MJC MDS/AML 13: CIBMTR Analysis of HCT in Older Patients with AML or MDS
CIBMTR Analysis of HCT in Older Patients with AML or MDS
5MJC MDS/AML 12: New Prognostic Markers in Acute Myeloid Leukemia (AML)
New Prognostic Markers in Acute Myeloid Leukemia (AML)